You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
|
|---|---|
| Published in |
Biologics: Targets & Therapy, February 2016
|
| DOI | 10.2147/btt.s67844 |
| Pubmed ID | |
| Authors |
Josephine Emole, Taiwo Talabi, Javier Pinilla-Ibarz |
| Abstract |
Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by the presence of the Philadelphia chromosome and the bcr-abl gene. The discovery of tyrosine kinase inhibitors (TKIs) revolutionized therapy for CML, such that durable response, increased overall survival, and increased progression-free survival of patients in chronic phase CML is now possible. Due to resistance and intolerance to imatinib, there was need for development of second- and third-generation TKIs for the treatment of CML. This review examines the role of nilotinib, an oral second-generation TKI, in the treatment of Philadelphia positive CML. The pharmacology, efficacy, and safety of nilotinib are critically evaluated. Patient-related issues, including tolerance, drug interactions, and quality of life issues are also examined. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 2% |
| Unknown | 42 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 19% |
| Student > Bachelor | 7 | 16% |
| Student > Postgraduate | 4 | 9% |
| Professor | 3 | 7% |
| Other | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 14 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 26% |
| Biochemistry, Genetics and Molecular Biology | 6 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 12% |
| Agricultural and Biological Sciences | 2 | 5% |
| Chemistry | 2 | 5% |
| Other | 3 | 7% |
| Unknown | 14 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 February 2016.
All research outputs
#19,944,091
of 25,373,627 outputs
Outputs from Biologics: Targets & Therapy
#214
of 284 outputs
Outputs of similar age
#283,607
of 406,424 outputs
Outputs of similar age from Biologics: Targets & Therapy
#5
of 7 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,424 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.